Compounds · subcategory
Cagrilintide & amylin analogues
Long-acting amylin analogues alone and in combination. Mechanism, published data, and the open questions.
24 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Amylin analogue mechanism: satiety signalling separate from GLP-1
Amylin analogue mechanism: satiety signalling separate from GLP-1 — setting out what I have, and where I think it stops being reliable. Trying to work out what would count as evidence on amylin analogue…
|
+128 | 142 | 38k | 13mo |
|
The CagriSema phase 2 paper and what a fixed combination buys — the long version
The CagriSema phase 2 paper and what a fixed combination buys — the long version Writing it up because I had to work it out twice and would rather nobody else did. A narrow question about CagriSema phase 2…
|
+137 | 158 | 17k | 13mo |
|
What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism — that is the question, and I have not found it answered plainly anywhere I have looked. A comparison question rather than a question about one…
|
+83 | 91 | 46k | 1d |
|
Why cagrilintide alone is discussed so much less than in combination
Why cagrilintide alone is discussed so much less than in combination I have a specific reason for asking rather than idle curiosity, and the context is below. Collecting what is known about cagrilintide alone…
|
+93 | 108 | 35k | 16mo |
|
Cagrilintide's dosing interval and the pharmacokinetics behind it
Cagrilintide's dosing interval and the pharmacokinetics behind it — setting out what I have, and where I think it stops being reliable. Putting the numbers in the first post, because a question about a…
|
+98 | 105 | 24k | 10mo |
|
The CagriSema phase 2 paper and what a fixed combination buys
Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. Working notes on cagrisema phase 2 paper rather than a…
|
+88 | 93 | 29k | 11mo |
|
Nausea profile of amylin analogues compared with GLP-1 agonists
Nausea profile of amylin analogues compared with GLP-1 agonists Writing it up because I had to work it out twice and would rather nobody else did. I have spent a fortnight trying to pin nausea profile of…
|
+70 | 76 | 3k | 4mo |
|
Coming back to: Nausea profile of amylin analogues compared with GLP-1 agonists
Posting this under the heading it deserves: Nausea profile of amylin analogues compared with GLP-1 agonists Everything below is what sits behind that. Nausea profile of amylin analogues — I have the…
|
+48 | 53 | 31k | 13mo |
|
Historical amylin analogues and what happened to them
Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. Proposing that historical amylin analogues deserves a maintained…
|
+29 | 36 | 31k | 1d |
|
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins
Amylin and gastric emptying: overlapping mechanisms with incretins — setting out what I have, and where I think it stops being reliable. A question about Amylin and gastric emptying that I think has a…
|
+21 | 25 | 44k | 5mo |
|
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold?
Amylin analogue mechanism: satiety signalling separate from GLP-1 — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Trying to work out what would…
|
+21 | 25 | 45k | 7mo |
|
Amylin and gastric emptying: overlapping mechanisms with incretins
On the subject in the title: Amylin and gastric emptying: overlapping mechanisms with incretins Working notes rather than a conclusion. Posting a small dataset on amylin and gastric emptying. It is mine, it…
|
2 | 50k | 17mo | |
|
Second pass at: Reading a combination trial: attributing effect to components
Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable. The question about Reading a combination trial that I…
|
+39 | 43 | 7.3k | 12mo |
|
Cagrilintide molecular characteristics and analytical considerations
Cagrilintide molecular characteristics and analytical considerations — setting out what I have, and where I think it stops being reliable. A methods question rather than a substantive one, about cagrilintide…
|
4 | 41k | 12mo | |
|
Why cagrilintide alone is discussed so much less than in combination — does this still hold?
Why cagrilintide alone is discussed so much less than in combination — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Cagrilintide alone:…
|
+27 | 31 | 1.2k | 22h |
|
Second pass at: Historical amylin analogues and what happened to them
Second pass at: Historical amylin analogues and what happened to them — setting out what I have, and where I think it stops being reliable. The question about Historical amylin analogues that I actually want…
|
+15 | 19 | 22k | 18mo |
|
Follow-up: Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because a question about…
|
2 | 41k | 14mo | |
|
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1
On the subject in the title: Amylin analogue mechanism: satiety signalling separate from GLP-1 Working notes rather than a conclusion. Trying to work out what would count as evidence on Amylin analogue…
|
+27 | 31 | 671 | 12mo |
|
Reading a combination trial: attributing effect to components
On the subject in the title: Reading a combination trial: attributing effect to components Working notes rather than a conclusion. Collecting what is known about reading a combination trial in one place,…
|
4 | 19k | 11mo | |
|
Is "synergy" the right word for the combination data?
Is "synergy" the right word for the combination data? — that is the question, and I have not found it answered plainly anywhere I have looked. Setting out what I think I know about this compound and asking…
|
+5 | 9 | 13k | 25d |
|
Follow-up: What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism I have a specific reason for asking rather than idle curiosity, and the context is below. Putting the numbers in the first post, because a question…
|
2 | 25k | 11mo | |
|
Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it
On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion. A comparison question rather than a question about one…
|
+2 | 6 | 2.4k | 7mo |
|
About the Cagrilintide & amylin analogues category
Long-acting amylin analogues alone and in combination. Mechanism, published data, and the open questions. This post is a community wiki: any member at trust level 3 or above can edit it, and every edit is…
|
4 | 1.8k | 11mo | |
|
Second pass at: Cagrilintide molecular characteristics and analytical considerations
On the subject in the title: Second pass at: Cagrilintide molecular characteristics and analytical considerations Working notes rather than a conclusion. Something about Cagrilintide molecular characteristics…
|
4 | 5k | 21d |